

# Anna Gluba-Brzzka

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8771174/anna-gluba-brzozka-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

69

papers

1,542

citations

21

h-index

37

g-index

76

ext. papers

1,978

ext. citations

4.1

avg, IF

5.02

L-index

#	Paper	IF	Citations
69	The role of Toll-like receptors in renal diseases. <i>Nature Reviews Nephrology</i> , <b>2010</b> , 6, 224-35	14.9	145
68	Lipid-modifying effects of nutraceuticals: An evidence-based approach. <i>Nutrition</i> , <b>2016</b> , 32, 1179-92	4.8	133
67	Novel Biomarkers in the Diagnosis of Chronic Kidney Disease and the Prediction of Its Outcome. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	112
66	The sirtuin family members SIRT1, SIRT3 and SIRT6: Their role in vascular biology and atherogenesis. <i>Atherosclerosis</i> , <b>2017</b> , 265, 275-282	3.1	106
65	The risk of atherosclerosis in patients with chronic kidney disease. <i>International Urology and Nephrology</i> , <b>2013</b> , 45, 1605-12	2.3	60
64	The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk. <i>Lipids in Health and Disease</i> , <b>2017</b> , 16, 207	4.4	56
63	Metabolic syndrome and renal disease. <i>International Journal of Cardiology</i> , <b>2013</b> , 164, 141-50	3.2	52
62	Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance. <i>Current Pharmaceutical Design</i> , <b>2013</b> , 19, 4904-12	3.3	47
61	The Effect of Diet on the Survival of Patients with Chronic Kidney Disease. <i>Nutrients</i> , <b>2017</b> , 9,	6.7	43
60	An update on biomarkers of heart failure in hypertensive patients. <i>Journal of Hypertension</i> , <b>2012</b> , 30, 1681-9	1.9	43
59	Vegetarian Diet in Chronic Kidney Disease-A Friend or Foe. <i>Nutrients</i> , <b>2017</b> , 9,	6.7	42
58	Molecular mechanisms of statin intolerance. <i>Archives of Medical Science</i> , <b>2016</b> , 12, 645-58	2.9	40
57	The role of polymorphisms within paraoxonases (192 Gln/Arg in PON1 and 311Ser/Cys in PON2) in the modulation of cardiovascular risk: a pilot study. <i>Angiology</i> , <b>2010</b> , 61, 157-65	2.1	38
56	Role and significance of statins in the treatment of hypertensive patients. <i>Current Medical Research and Opinion</i> , <b>2009</b> , 25, 1995-2005	2.5	34
55	Markers of increased cardiovascular risk in patients with chronic kidney disease. <i>Lipids in Health and Disease</i> , <b>2014</b> , 13, 135	4.4	33
54	The Impact of CKD on Uremic Toxins and Gut Microbiota. <i>Toxins</i> , <b>2021</b> , 13,	4.9	27
53	Heart function disturbances in chronic kidney disease - echocardiographic indices. <i>Archives of Medical Science</i> , <b>2014</b> , 10, 1109-16	2.9	26

52	The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	25
51	Biomarkers and echocardiographic predictors of myocardial dysfunction in patients with hypertension. <i>Scientific Reports</i> , <b>2015</b> , 5, 8916	4.9	25
50	The multi-biomarker approach for heart failure in patients with hypertension. <i>International Journal of Molecular Sciences</i> , <b>2015</b> , 16, 10715-33	6.3	24
49	Prevention of sudden cardiac death in patients with chronic kidney disease. <i>BMC Nephrology</i> , <b>2012</b> , 13, 162	2.7	23
48	Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. <i>Scientific Reports</i> , <b>2016</b> , 6, 30060	4.9	21
47	Treatment of non-ST-elevation myocardial infarction and ST-elevation myocardial infarction in patients with chronic kidney disease. <i>Archives of Medical Science</i> , <b>2013</b> , 9, 1019-27	2.9	20
46	The Influence of Inflammation on Anemia in CKD Patients. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	19
45	Impact of Vitamin D on the Cardiovascular System in Advanced Chronic Kidney Disease (CKD) and Dialysis Patients. <i>Nutrients</i> , <b>2018</b> , 10,	6.7	19
44	Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study. <i>Lipids in Health and Disease</i> , <b>2016</b> , 15, 22	4.4	19
43	Sudden cardiac death in CKD patients. <i>International Urology and Nephrology</i> , <b>2015</b> , 47, 971-82	2.3	18
42	Is polymorphism within eNOS gene associated with the late onset of myocardial infarction? A pilot study. <i>Angiology</i> , <b>2009</b> , 60, 588-95	2.1	18
41	The Use of Plant Sterols and Stanols as Lipid-Lowering Agents in Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , <b>2017</b> , 23, 2488-2495	3.3	18
40	Relationship between long noncoding RNAs and physiological risk factors of cardiovascular disease. <i>Journal of Clinical Lipidology</i> , <b>2017</b> , 11, 617-623	4.9	17
39	Statins in patients with chronic kidney disease: why, who and when?. <i>Expert Opinion on Pharmacotherapy</i> , <b>2010</b> , 11, 2665-74	4	16
38	Serum NGAL, KIM-1, IL-18, L-FABP: new biomarkers in the diagnostics of acute kidney injury (AKI) following invasive cardiology procedures. <i>International Urology and Nephrology</i> , <b>2020</b> , 52, 2135-2143	2.3	14
37	Acute coronary syndromes in patients with chronic kidney disease. <i>Current Vascular Pharmacology</i> , <b>2013</b> , 11, 758-67	3.3	14
36	Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease. <i>Expert Opinion on Investigational Drugs</i> , <b>2015</b> , 24, 603-10	5.9	13
35	Do HDL and LDL subfractions play a role in atherosclerosis in end-stage renal disease (ESRD) patients?. <i>International Urology and Nephrology</i> , <b>2017</b> , 49, 155-164	2.3	12

34	Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 1857-1865	4	12
33	High-Density Lipoprotein and Low-Density Lipoprotein Subfractions in Patients with Chronic Kidney Disease. <i>Current Vascular Pharmacology</i> , <b>2017</b> , 15, 144-151	3.3	11
32	Combination drug versus monotherapy for the treatment of autosomal dominant polycystic kidney disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 2049-56	4	11
31	Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge. <i>International Urology and Nephrology</i> , <b>2015</b> , 47, 805-13	2.3	10
30	Pharmacogenomics of Hypertension Treatment. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	10
29	Assessment of the relationship between selected cardiovascular risk factors and the indices of intima-media thickness and coronary artery calcium score in various stages of chronic kidney disease. <i>International Urology and Nephrology</i> , <b>2015</b> , 47, 2003-12	2.3	8
28	Oxidative Stress in ESRD Patients on Dialysis and the Risk of Cardiovascular Diseases. <i>Antioxidants</i> , <b>2020</b> , 9,	7.1	8
27	The Problem of Atrial Fibrillation in Patients with Chronic Kidney Disease. <i>Current Vascular Pharmacology</i> , <b>2016</b> , 14, 260-5	3.3	8
26	Cholesterol Subfraction Analysis in Patients with Acute Coronary Syndrome. <i>Current Vascular Pharmacology</i> , <b>2019</b> , 17, 365-375	3.3	8
25	Cholesterol Disturbances and the Role of Proper Nutrition in CKD Patients. <i>Nutrients</i> , <b>2019</b> , 11,	6.7	8
24	Morphine-mediated alteration of hypertension-related gene expression in human white blood cells and multilineage progenitor cells. <i>Journal of Human Hypertension</i> , <b>2010</b> , 24, 713-20	2.6	7
23	Biochemical Markers in the Prediction of Contrast-induced Acute Kidney Injury. <i>Current Medicinal Chemistry</i> , <b>2021</b> , 28, 1234-1250	4.3	7
22	Hypertension - Current Natural Strategies to Lower Blood Pressure. <i>Current Pharmaceutical Design</i> , <b>2017</b> , 23, 2453-2461	3.3	6
21	The Correlation between Lipid Metabolism Disorders and Prostate Cancer. <i>Current Medicinal Chemistry</i> , <b>2021</b> , 28, 2048-2061	4.3	6
20	The occurrence of atrial fibrillation in dialysis patients and its association with left atrium volume before and after dialysis. <i>International Urology and Nephrology</i> , <b>2017</b> , 49, 1071-1077	2.3	5
19	The Role of Metabolic Factors in Renal Cancers. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	5
18	Are Markers of Cardiac Dysfunction Useful in the Assessment of Cardiovascular Risk in Dialysis Patients?. <i>Current Pharmaceutical Design</i> , <b>2017</b> , 23, 3024-3033	3.3	4
17	Lipoprotein Subfractions, Uric Acid and Cardiovascular Risk in End-Stage Renal Disease (ESRD) Patients. <i>Current Vascular Pharmacology</i> , <b>2017</b> , 15, 123-134	3.3	3

16	Diabetes and Cardiovascular Risk in Renal Transplant Patients. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	3
15	miRNA biomarkers in renal disease. <i>International Urology and Nephrology</i> , <b>2021</b> , 1	2.3	3
14	Are Nutraceuticals Beneficial in Chronic Kidney Disease?. <i>Pharmaceutics</i> , <b>2021</b> , 13,	6.4	3
13	Two polymorphisms of the FVII gene and their impact on the risk of myocardial infarction in poles under 45 years of age. <i>Molecular Biology</i> , <b>2010</b> , 44, 202-207	1.2	2
12	Emerging Anti-Atherosclerotic Therapies. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	2
11	Biomarkers of Cardiovascular Risk in Haemodialysis Patients. <i>Current Pharmaceutical Design</i> , <b>2018</b> , 23, 6086-6095	3.3	2
10	Diabetes-induced Alterations in HDL Subfractions Distribution. <i>Current Pharmaceutical Design</i> , <b>2020</b> , 26, 3341-3348	3.3	2
9	Metabolomic Profile in Venous Thromboembolism (VTE). <i>Metabolites</i> , <b>2021</b> , 11,	5.6	2
8	Oxidative Stress-Related Susceptibility to Aneurysm in Marfan's Syndrome. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	2
7	Pathomechanisms of Immunological Disturbances in $\beta$ -Thalassemia. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	2
6	Definition and Characteristics of Hypertension Associated with Chronic Kidney Disease: Epidemiological Data <b>2017</b> , 13-23		1
5	Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal Diseases. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	1
4	Are polymorphisms within endothelial nitric oxide synthase good predictors of coronary artery disease?. <i>Cardiology</i> , <b>2010</b> , 116, 268-70	1.6	1
3	Is a High HDL-Cholesterol Level Always Beneficial?. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	1
2	Microarray technology in the study of genetic determinants of cardiovascular diseases. <i>Open Medicine (Poland)</i> , <b>2009</b> , 4, 1-10	2.2	
1	Evaluation of the effectiveness of methods of endoscopic treatment of bleeding from the duodenal mucosa. <i>Polski Merkurusz Lekarski</i> , <b>2015</b> , 38, 77-81	0.4	